Paper Details

  1. Home
  2. Paper Details

The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer.

Author: AleiwiBilal, CarapellucciSarah, EllsworthEdmund, Krieger-BurkeTeresa, LealAna S, LibyKaren T, LockwoodBeth, MoerlandJessica A, ZhangDi

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the immunomodulatory and anti-tumor effects of MSU42011, a new RXR agonist, in two different immunocompetent murine models of cancer. The study found that MSU42011 significantly decreased the tumor burden and increased the ratio of CD8/CD4, CD25 T cells in both models. This suggests that MSU42011 can modulate the tumor microenvironment in breast and lung cancer.
Paper Details　
Original Abstract of the Article :
(1) Background: Notwithstanding numerous therapeutic advances, 176,000 deaths from breast and lung cancers will occur in the United States in 2021 alone. The tumor microenvironment and its modulation by drugs have gained increasing attention and relevance, especially with the introduction of immunot...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508021/

データ提供：米国国立医学図書館（NLM）

MSU42011: A Promising RXR Agonist for Breast and Lung Cancer Treatment

This study investigates the potential therapeutic effects of MSU42011, a novel RXR agonist, in preclinical models of HER2-positive breast cancer and Kras-driven lung cancer. The research examines the immunomodulatory and anti-tumor effects of MSU42011, evaluating its impact on tumor growth, immune cell populations, and the efficacy of immunotherapy. The authors demonstrate the effectiveness of MSU42011 in modulating the tumor microenvironment, enhancing anti-tumor responses, and potentially synergizing with immunotherapy. This study contributes to the ongoing development of novel therapeutic approaches for breast and lung cancer, highlighting the potential of RXR agonists in cancer treatment.

MSU42011: A New Weapon in the Arsenal Against Cancer

This study reveals the promising potential of MSU42011, a novel RXR agonist, in the treatment of HER2-positive breast cancer and Kras-driven lung cancer. The findings demonstrate the effectiveness of MSU42011 in modulating the tumor microenvironment, enhancing anti-tumor responses, and potentially synergizing with immunotherapy. This research offers a compelling case for exploring the therapeutic potential of RXR agonists in the fight against cancer.

MSU42011: A Guiding Light in the Desert of Cancer Treatment

The desert of cancer treatment can be a daunting landscape, filled with challenges and uncertainties. This study provides a guiding light, demonstrating the potential of MSU42011, a novel RXR agonist, in effectively treating HER2-positive breast cancer and Kras-driven lung cancer. The findings highlight the significance of targeting the tumor microenvironment and exploring novel therapeutic approaches, offering hope for improved patient outcomes and a brighter future in the fight against cancer.

Dr.Camel's Conclusion

This study investigates the potential therapeutic effects of MSU42011, a novel RXR agonist, in preclinical models of HER2-positive breast cancer and Kras-driven lung cancer. The findings demonstrate the effectiveness of MSU42011 in modulating the tumor microenvironment, enhancing anti-tumor responses, and potentially synergizing with immunotherapy. This research offers a compelling case for exploring the therapeutic potential of RXR agonists in the fight against cancer.
Date :
  1. Date Completed n.d.
  2. Date Revised 2023-11-07
Further Info :

Pubmed ID

34638488

DOI: Digital Object Identifier

PMC8508021

Related Literature

Article Analysis
・Effects of bexarotene
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.